International treatment involving more than one substance requires a combined clinical assessment before choosing a program or booking travel. A center may be equipped for one part of the picture and need another service for the rest. Ask how it will assess the whole pattern, decide the appropriate setting, and coordinate treatment rather than simply offering several separate detox packages.
The CDC describes polysubstance use as exposure to more than one drug, with or without the person’s knowledge. The term identifies an important assessment issue, but does not tell a clinician which diagnoses, interventions, or level of care apply. Those decisions depend on the actual substances and circumstances.
Give the clinician a complete account
List alcohol, prescribed medicines, nonprescription products, and other substances. Describe what is used together, what is used at different times, and what has changed recently. Include products whose contents are uncertain. The assessment should not depend on the patient knowing the exact chemical composition of an unfamiliar substance.
Explain the role each substance appears to play. A person may describe using one during social events, another afterward, and a prescribed medicine on ordinary workdays. Another person may have a different pattern entirely. These accounts help the clinician understand the sequence without assuming that every combination has the same motive or clinical significance.
Bring previous treatment records and describe withdrawal experiences, hospital admissions, overdose, and mental health care where relevant. It is better to identify uncertainty than to minimize a substance because it feels secondary. A detail that seems less important to the patient may change the professional assessment of travel or treatment suitability.
Do not assume substances balance each other
The CDC’s polysubstance information explains that stimulants and depressants do not cancel each other out. Combinations can have unpredictable effects and can mask how strongly a drug is affecting someone. A feeling of being more alert does not establish that a person is medically safe.
This matters when planning admission. Tell the assessing clinician what has been used recently rather than assuming that the apparent effect of one substance reveals the whole situation. Serious physical symptoms, a suspected overdose, or immediate danger require local emergency help, not a wait for an overseas program to become available.
The assessment before treatment abroad guide helps organize the information to share. An administrative admissions call can collect details, but the provider should explain who makes the clinical decision and whether a local examination or additional records are needed before travel.
Ask for one assessment with clearly separated decisions
A combined plan should distinguish immediate medical needs, withdrawal-related concerns, ongoing substance use treatment, and other physical or mental health conditions. These issues interact, but they are not the same. Ask the clinician to explain which decisions need to happen first and which parts of care can proceed together.
For example, the need for a medical setting during one phase does not by itself determine the entire rehabilitation plan. Equally, a suitable psychotherapy program may not have the medical capability required at the start. The proposal should explain the relationship between phases rather than present the same location as automatically suitable for every stage.
Ask what the center can provide directly and what requires a separate hospital, prescriber, or specialist. If the plan depends on outside care, confirm that the arrangement exists and that the receiving service has the necessary information. A list of possible referral partners does not establish an accepted clinical handover.
Make withdrawal planning substance-specific
Different substances and medicines can create different withdrawal concerns. Alcohol dependence, opioid use disorder, benzodiazepine dependence, and stimulant-related difficulties should not be collapsed into one standard timetable. Ask the responsible clinician how the full history affects the setting and sequence of care.
The ASAM alcohol withdrawal guideline separates withdrawal management from ongoing treatment for alcohol use disorder. Its benzodiazepine tapering guideline emphasizes individualized clinical decisions. A program should be able to explain the relevant approach for each concern without asking the patient to follow a generic internet protocol.
Do not abruptly stop alcohol or dependence-forming medicines to meet an admission condition. Discuss proposed changes with a qualified clinician who knows the combined history. The international polysubstance withdrawal guide examines how to evaluate this phase while leaving dosing and sequencing decisions to the treating professionals.
Preserve effective treatment while addressing interaction risks
Risks from combining substances do not automatically mean established treatment should be withheld. The CDC’s 2022 clinical practice guideline specifically advises against withholding methadone or buprenorphine for opioid use disorder solely because a person takes benzodiazepines or other central nervous system depressants. It recognizes both the increased risks of combined use and the potential harm of untreated opioid use disorder. These decisions require careful clinical management.
This is a decision for qualified clinicians, not permission to combine medicines or change treatment without advice. Ask the international program how it will coordinate with the current prescriber. If it proposes stopping an established medicine, request the clinical rationale and discuss it with the professional already responsible for that treatment.
The opioid treatment continuity guide explains why access must be confirmed across the journey. For a person taking several medicines, one accurate list and clear responsibility are especially important. The patient should not receive contradictory instructions from different teams without a process to resolve them.
Evaluate the ongoing therapy plan
Ask how treatment will address the circumstances around each substance and the relationships between them. If a pattern changes after one substance is reduced, who reassesses the plan? A program should not treat the first identified substance as the only relevant concern or assume that addressing it automatically resolves every other pattern.
Request an explanation of the interventions and their purpose. The WHO and UNODC international treatment standards describe treatment systems with different settings and interventions. When comparing individual providers, ask which components the proposed program actually delivers and how they relate to the assessment.
A long weekly schedule is not enough to answer that question. Distinguish professional therapy, clinical review, practical support, peer activities, and recreation. Each may contribute something different. The relevant issue is whether the program’s clinical content addresses the person’s needs and how progress will be reviewed.
Agree how progress will be reviewed
Before treatment begins, agree how progress will be discussed across the different concerns. A change in one pattern does not tell the team everything about another. Ask whether reviews consider substance use, health, attendance, daily functioning, and the person’s own goals. If testing is part of treatment, the clinician should explain its purpose and limitations rather than presenting a result as the entire assessment.
Also ask what prompts a change in the plan. The answer should identify who reviews new information and how decisions are shared with the patient. This makes progress a clinical conversation rather than a single pass-or-fail judgment at discharge.
Make co-occurring mental health care explicit
Tell the team about depression, anxiety, trauma symptoms, psychosis, ADHD, or any other assessed concern. Ask who evaluates changes in mental health and how the person can access help outside scheduled sessions. A center’s broad “dual diagnosis” claim should become a clear description of the care available for the particular condition.
The integrated international care guide explores coordination between services. If a current psychiatrist or therapist is involved, agree how relevant information will be shared. A new symptom should not automatically be attributed to withdrawal, and a previous diagnosis should not prevent assessment of substance-related effects.
Ask how the provider distinguishes a manageable difficulty within its program from a need for hospital care. This is especially important when the center is remote or when language could complicate an urgent transfer. The plan should identify the actual response rather than rely on a general promise that help is nearby.
Check travel, medication, and costs as part of the clinical proposal
The CDC Yellow Book discusses international substance use treatment and medicine restrictions. Verify the requirements for every medicine that may be carried or needed during travel, including transit locations. Clinical acceptance by a program and legal permission to transport medication are separate questions.
Confirm whether the quoted price covers separate medical care, specialist reviews, tests, medicine, transport, and changes in the level of support. A package may be priced around the residential phase while another service handles a necessary earlier phase. Ask for the whole pathway in writing so the comparison reflects the care actually proposed.
Discuss what happens if the person cannot travel on the expected date, needs a different setting on arrival, or leaves early. The plan should preserve access to essential care and identify the responsible professional. Administrative flexibility is useful only when it connects with an appropriate clinical response.
Plan for the first weeks at home
Agree which professionals will continue each part of care and when appointments will occur. Ask for a discharge summary that explains the substances assessed, diagnoses or uncertainties, interventions, medication decisions, and outstanding needs. The receiving team should not have to reconstruct the plan from a generic completion letter.
The aftercare handover guide can help organize these details. Discuss the situations at home that are relevant to the person’s pattern of use and the support available when difficulties recur. A useful international plan integrates the whole picture while keeping individual treatment responsibilities clear.